29115-34-2
Chemical Structure
MCC1019
- CAS No.: 29115-34-2
- Formula:C12H11BrO3
- Molecular Weight:283.12
IUPAC Name: ethyl 3-(bromomethyl)benzofuran-2-carboxylate
InChIKey: AHTASHQCOAXTTF-UHFFFAOYSA-N
SMILES: O=C(OCC)C=1OC=2C=CC=CC2C1CBr
Biological Activity: MCC1019 is a selective PLK1 PBD inhibitor with an IC50 of 16.4 μmol/L. MCC1019 inactivates the AKT signaling pathway in cancer cells, and induces Apoptosis, Necroptosis and Autophagy. MCC1019 exhibits anticancer activity against lung cancer and prostate cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MCC1019 | MCC1019 is a selective PLK1 PBD inhibitor with an IC50 of 16.4 μmol/L. MCC1019 inactivates the AKT signaling pathway in cancer cells, and induces Apoptosis, Necroptosis and Autophagy. MCC1019 exhibits anticancer activity against lung cancer and prostate cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Farhat J, et al. Structure-Activity Relationship of Benzofuran Derivatives with Potential Anticancer Activity. Cancers (Basel). 2022;14(9):2196. Published 2022 Apr 28. [Content Brief]
- [2]. Abdelfatah S, et al. MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate. Acta Pharm Sin B. 2019;9(5):1021-1034. [Content Brief]
Keywords